Company intelligence / Profile preview

Guangzhou Huahai Pharmaceutical

Guangzhou, Guangdong Sheng, Chinaen.huahaipharm.com ↗

Ownership: Private
Development stage: Other

Overview

Guangzhou Huahai Pharmaceutical is a private Chinese pharmaceutical company focused on the development and commercialization of traditional Chinese medicines and herbal drugs. As of early 2025, it has at least two programs in Phase 2 clinical trials—one for irritable bowel syndrome with diarrhea and another for non-small cell lung cancer—and one pending program for gouty arthritis. The company’s pipeline is primarily based on herbal formulations. There are no published results from pivotal or late-stage clinical trials.

Therapeutic areas: GastroenterologyRheumatologyOncology
Modalities: Herbal medicineSmall molecule
Industry: Biotech

Drug pipeline

1 asset

Renzhu Changle Granule

Unknown

Beyond the preview

Go deeper on Guangzhou Huahai Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangzhou Huahai Pharmaceutical.

Explore the full profile